After a dearth of advances on the treatment of Alzheimer’s disease for many years, June has become the month of action, with conditional US regulatory approval for the first treatment in 20 years, and two investigational drugs gaining Breakthrough status.
The latest news yesterday saw the US Food and Drug Administration grant Breakthrough Therapy designation (BTD) for donanemab, US pharma major Eli Lilly’s (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD).
Lilly’s shares closed up 7.3% at $232.97 yesterday following the announcement, which came just a day after Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) were granted BTD for their AD candidate lecanemab (BAN2401).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze